Robert W. Baird & Co. Incorporated on Alkermes
Thesis
Baird initiated a position in Alkermes as part of its increased exposure to commercial-stage therapeutics. The company is one of only a few businesses with a leading product in the Orexin receptor category. Baird believes this category offers promising growth potential in wakefulness and potentially additional indications.
“Alkermes is one of a few companies with a lead product in the Orexin receptor category”